[Federal Register Volume 73, Number 179 (Monday, September 15, 2008)]
[Notices]
[Pages 53254-53258]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-21450]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0480]
Animal Drug User Fee Rates and Payment Procedures for Fiscal Year
2009
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the rates
and payment procedures for fiscal year (FY) 2009 for user fees under
the Animal Drug User Fee Act program (ADUFA). The Federal Food, Drug,
and Cosmetic Act (the act), as amended by the Animal Drug User Fee Act
of 2003 (ADUFA I), and the Animal Drug User Fee Amendments of 2008
(ADUFA II), authorizes FDA to collect user fees for certain animal drug
applications, on certain animal drug products, on certain
establishments where such products are made, and on certain sponsors of
such animal drug applications and/or investigational animal drug
[[Page 53255]]
submissions. This notice establishes the fee rates for FY 2009.
For FY 2009, the animal drug user fee rates are: $246,300 for an
animal drug application; $123,150 for a supplemental animal drug
application for which safety or effectiveness data is required and for
an animal drug application subject to certain criteria; $4,925 for an
annual product fee; $59,450 for an annual establishment fee; and
$52,700 for an annual sponsor fee. FDA will issue invoices for FY 2009
product, establishment, and sponsor fees by December 31, 2008, and
these invoices will be due and payable on or before January 31, 2009.
FDA will issue invoices in November 2009 for any products,
establishments, and sponsors that are subject to fees for FY 2009 but
that qualified for fees after the December 2008 billing.
The application fee rates are effective for applications submitted
on or after October 1, 2008, and will remain in effect through
September 30, 2009. Applications will not be accepted for review until
FDA has received full payment of application fees and any other animal
drug user fees owed.
FOR FURTHER INFORMATION CONTACT: Visit the FDA Web site at http://www.fda.gov/oc/adufa or contact Roxanne Schweitzer, Center for
Veterinary Medicine (HFV-10), Food and Drug Administration, 7529
Standish Pl., Rockville, MD 20855, 240-276-9705. For general questions,
you may also e-mail the Center for Veterinary Medicine at:
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Section 740 of the act (21 U.S.C. 379j-12) establishes four
different kinds of user fees: (1) Fees for certain types of animal drug
applications and supplements, (2) annual fees for certain animal drug
products, (3) annual fees for certain establishments where such
products are made, and (4) annual fees for certain sponsors of animal
drug applications and/or investigational animal drug submissions
(section 740(a) of the act). When certain conditions are met, FDA will
waive or reduce fees (section 740(d) of the act).
For FY 2009 through FY 2013, the act establishes aggregate yearly
base revenue amounts for each of these fee categories. Base revenue
amounts established for years after FY 2009 are subject to adjustment
for workload. Fees for applications, products, establishments, and
sponsors are to be established each year by FDA so that the revenue for
each fee category will approximate the level established in the
statute, after the level has been adjusted for workload.
II. Revenue Amount for FY 2009
A. Statutory Fee Revenue Amounts
ADUFA II (Public Law 110-316 signed by the President on August 14,
2008) specifies that the aggregate revenue amount for FY 2009 for each
of the four animal drug user fee categories is $3,815,000, before any
adjustment for workload is made (see section 740(b)(1) through (b)(4)
of the act).
B. Inflation Adjustment to Fee Revenue Amount
Because the amounts established in ADUFA II for each year for FY
2009 through FY 2013 include an inflation adjustment, no further
inflation adjustment is required.
C. Workload Adjustment to Fee Revenue Amount
For each FY beginning after FY 2009, ADUFA II provides that
statutory fee revenue amounts shall be further adjusted to reflect
changes in review workload (section 740(c)(1) of the act). No workload
adjustment is to be made in fee revenue amounts for FY 2009.
III. Adjustment for Excess Collections in Previous Years
Under the provisions of ADUFA I, if the agency collects more fees
than were provided for in appropriations in any year, FDA is required
to reduce its anticipated fee collections in a subsequent year by that
amount (section 740(g)(4) of the act). Table 1 of this document shows
the amount of collections realized and the amount provided in
appropriations acts, and the amount to be offset in a subsequent year,
as of the end of the latest complete fiscal year, 2007.
Table 1--Fees Collected, Fees Appropriated, and Offset for Future Collections as of September 30, 2007
----------------------------------------------------------------------------------------------------------------
Amount to Offset Future
Fiscal Year Collections Realized Fees Appropriated Collections
----------------------------------------------------------------------------------------------------------------
2004 $5,154,700 $5,000,000 $154,700
----------------------------------------------------------------------------------------------------------------
2005 $8,519,101 $8,354,000 $165,101
----------------------------------------------------------------------------------------------------------------
2006 $10,945,866 $11,318,000 $0
----------------------------------------------------------------------------------------------------------------
2007 $12,946,515 $11,604,000 $1,342,515
----------------------------------------------------------------------------------------------------------------
Total $1,662,316
----------------------------------------------------------------------------------------------------------------
Amount offset when fees for FY 2008 were determined $320,000
----------------------------------------------------------------------------------------------------------------
Remaining balance to be offset in FY 2009 $1,342,316
----------------------------------------------------------------------------------------------------------------
When ADUFA fees were established for FY 2008, the amount of fee
revenues for FY 2008 was reduced by a total of $320,000 of excess
collections. That leaves a total of $1,342,316 to be offset against FY
2009 revenue collections, lowering the net amount that would otherwise
be collected. One-fourth of this amount, rounded to the nearest
thousand, or $336,000, rounded to the nearest thousand dollars, will be
subtracted from the statutory fee revenue amounts for each of the four
fee categories in setting the FY 2009 adjusted revenue amount for each
fee category. Thus, after adjustment for prior-year excess collections,
the adjusted FY 2009 revenue target for each fee category is as
follows:
Application Fee Revenue Amount: $3,479,000 ($3,815,000 minus
$336,000)
Establishment Fee Revenue Amount: $3,479,000 ($3,815,000 minus
$336,000)
Product Fee Revenue Amount: $3,479,000 ($3,815,000 minus $336,000)
Sponsor Fee Revenue Amount: $3,479,000 ($3,815,000 minus $336,000)
[[Page 53256]]
Thus, the adjusted revenue amount from all four categories after this
adjustment totals $13,916,000.
IV. Application Fee Calculations for FY 2009
The terms ``animal drug applications'' and ``supplemental animal
drug applications'' are defined in section 739(1) and (2) of the act
(21 U.S.C. 379j-11(1) and (2)).
A. Application Fee Revenues and Numbers of Fee-Paying Applications
The application fee must be paid for any animal drug application or
supplemental animal drug application that is subject to fees under
ADUFA and that is submitted on or after September 1, 2003. The
application fees are to be set so that they will generate $3,479,000 in
fee revenue for FY 2009. This is the amount set out in the statute
after it has been adjusted for excess collections in previous years as
set out in section III of this document. The fee for a supplemental
animal drug application for which safety or effectiveness data are
required and for an animal drug application subject to criteria set
forth in section 512(d)(4) of the act (21 U.S.C. 360b(d)(4)) is to be
set at 50 percent of the animal drug application fee (see section
740(a)(1)(A)(ii) of the act, as amended by ADUFA II).
To set animal drug application fees and supplemental animal drug
application fees to realize $3,479,000, FDA must first make some
assumptions about the number of fee-paying applications and supplements
it will receive in FY 2009.
The agency knows the number of applications that have been
submitted in previous years. That number fluctuates significantly from
year to year. In estimating the fee revenue to be generated by animal
drug application fees in FY 2009, FDA is assuming that the number of
applications that will pay fees in FY 2009 will equal the average
number of submissions over the 4 most recent years (including an
estimate for the current year). This may not fully account for possible
year to year fluctuations in numbers of fee-paying applications, but
FDA believes that this is a reasonable approach after 5 years of
experience with this program.
Over the past 4 years, the average number of animal drug
applications that have been subject to the full fee was 7.5, including
the number for the most recent year, which is estimated at 4. Over this
same period, the average number of supplemental applications and
applications subject to the criteria set forth in section 512(d)(4)
that would have been subject to half of the full fee was 13.25,
including the number for the most recent year, which is estimated at 9.
Thus, for FY 2009, FDA estimates receipt of 7.5 fee paying original
applications and 13.25 fee-paying supplemental animal drug applications
and applications subject to the criteria set forth is section
512(d)(4), which pay half of the full fee.
B. Fee Rates for FY 2009
FDA must set the fee rates for FY 2009 so that the estimated 7.5
applications that pay the full fee and the estimated 13.25 supplements
and applications subject to the criteria set forth in section 512(d)(4)
that pay half of the full fee will generate a total of $3,479,000. To
generate this amount, the fee for an animal drug application, rounded
to the nearest hundred dollars, will have to be $246,300, and the fee
for a supplemental animal drug application for which safety or
effectiveness data are required and for applications subject to the
criteria set forth in section 512(d)(4) will have to be $123,150.
V. Product Fee Calculations for FY 2009
A. Product Fee Revenues and Numbers of Fee-Paying Products
The animal drug product fee (also referred to as the product fee)
must be paid annually by the person named as the applicant in an animal
drug application or supplemental animal drug application for an animal
drug product submitted for listing under section 510 of the act (21
U.S.C. 360), and who had an animal drug application or supplemental
animal drug application pending before FDA after September 1, 2003 (see
section 740(a)(2) of the act). The term ``animal drug product'' is
defined in section 739(3) of the act. The product fees are to be set so
that they will generate $3,479,000 in fee revenue for FY 2009. This is
the amount set out in the statute after it has been adjusted for excess
collections in previous years as set out in section III of this
document.
To set animal drug product fees to realize $3,479,000, FDA must
make some assumptions about the number of products for which these fees
will be paid in FY 2009. FDA developed data on all animal drug products
that have been submitted for listing under section 510 of the act, and
matched this to the list of all persons who had an animal drug
application or supplement pending after September 1, 2003. As of August
2008, FDA estimates that there are a total of 785 products submitted
for listing by persons who had an animal drug application or
supplemental animal drug application pending after September 1, 2003.
Based on this, FDA estimates that a total of 785 products will be
subject to this fee in FY 2009.
In estimating the fee revenue to be generated by animal drug
product fees in FY 2009, FDA is assuming that 10 percent of the
products invoiced, or about 78.5, will not pay fees in FY 2009 due to
fee waivers and reductions. Based on experience with other user fee
programs and the first 5 years of ADUFA, FDA believes that this is a
reasonable basis for estimating the number of fee-paying products in FY
2009.
Accordingly, the agency estimates that fees for a total of 706.5
products (785 minus 78.5) will be paid in FY 2009.
B. Product Fee Rates for FY 2009
FDA must set the fee rates for FY 2009 so that the estimated 706.5
products for which fees will be paid will generate a total of
$3,479,000. To generate this amount will require the fee for an animal
drug product, rounded to the nearest 5 dollars, to be $4,925.
VI. Establishment Fee Calculations for FY 2009
A. Establishment Fee Revenues and Numbers of Fee-Paying Establishments
The animal drug establishment fee (also referred to as the
establishment fee) must be paid annually by the person who: (1) Owns or
operates, directly or through an affiliate, an animal drug
establishment; (2) is named as the applicant in an animal drug
application or supplemental animal drug application for an animal drug
product submitted for listing under section 510 of the act; (3) had an
animal drug application or supplemental animal drug application pending
before FDA after September 1, 2003; and (4) whose establishment engaged
in the manufacture of the animal drug product during the FY (see
section 740(a)(3) of the act). An establishment subject to animal drug
establishment fees is assessed only one such fee per FY (see section
740(a)(3) of the act). The term ``animal drug establishment'' is
defined in section 739(4) of the act. The establishment fees are to be
set so that they will generate $3,479,000 in fee revenue for FY 2009.
This is the amount set out in the statute after it has been adjusted
for excess collections in previous years as set out in section III of
this document.
To set animal drug establishment fees to realize $3,479,000, FDA
must make some assumptions about the number of establishments for which
these fees will
[[Page 53257]]
be paid in FY 2009. FDA developed data on all animal drug
establishments and matched this to the list of all persons who had an
animal drug application or supplement pending after September 1, 2003.
As of August 2008, FDA estimates that there are a total of 65
establishments owned or operated by persons who had an animal drug
application or supplemental animal drug application pending after
September 1, 2003. Based on this, FDA believes that 65 establishments
will be subject to this fee in FY 2009.
In estimating the fee revenue to be generated by animal drug
establishment fees in FY 2009, FDA is assuming that 10 percent of the
establishments invoiced, or 6.5, will not pay fees in FY 2009 due to
fee waivers and reductions. Based on experience with the first 5 years
of ADUFA, FDA believes that this is a reasonable basis for estimating
the number of fee-paying establishments in FY 2009.
Accordingly, the agency estimates that fees for a total of 58.5
establishments (65 minus 6.5) will be paid in FY 2009.
B. Establishment Fee Rates for FY 2009
FDA must set the fee rates for FY 2009 so that the estimated 58.5
establishments for which fees will be paid will generate a total of
$3,479,000. To generate this amount will require the fee for an animal
drug establishment, rounded to the nearest 50 dollars, to be $59,450.
VII. Sponsor Fee Calculations for FY 2009
A. Sponsor Fee Revenues and Numbers of Fee-Paying Sponsors
The animal drug sponsor fee (also referred to as the sponsor fee)
must be paid annually by each person who: (1) Is named as the applicant
in an animal drug application that has not been withdrawn or has
submitted an investigational animal drug submission that has not been
terminated or otherwise rendered inactive and (2) had an animal drug
application, supplemental animal drug application, or investigational
animal drug submission pending before FDA after September 1, 2003 (see
sections 739(6) and 740(a)(4) of the act). An animal drug sponsor is
subject to only one such fee each FY (see section 740(a)(4) of the
act). The sponsor fees are to be set so that they will generate
$3,479,000 in fee revenue for FY 2009. This is the amount set out in
the statute after it has been adjusted for excess collections in
previous years as set out in section III of this document.
To set animal drug sponsor fees to realize $3,479,000, FDA must
make some assumptions about the number of sponsors who will pay these
fees in FY 2009. Based on the number of firms that would have met this
definition as of August 2008, FDA estimates that a total of 140
sponsors will meet this definition in FY 2009.
Careful review indicates that about one-third or 33 percent of all
of these sponsors will qualify for a minor use/minor species waiver or
reduction (section 740(d)(1)(C) of the act). Based on the agency's
experience with sponsor fees, FDA's current best estimate is that an
additional 20 percent will qualify for other waivers or reductions, for
a total of 53 percent of the sponsors invoiced, or 74 sponsors, who
will not pay fees in FY 2009 due to fee waivers and reductions. FDA
believes that this is a reasonable basis for estimating the number of
fee-paying sponsors in FY 2009.
Accordingly, the agency estimates that a total of 66 sponsors (140
minus 74) will pay sponsor fees in FY 2009.
B. Sponsor Fee Rates for FY 2009
FDA must set the fee rates for FY 2009 so that the estimated 66
sponsors that pay fees will generate a total of $3,479,000. To generate
this amount will require the fee for an animal drug sponsor, rounded to
the nearest 50 dollars, to be $52,700.
VIII. Fee Schedule for FY 2009
The fee rates for FY 2009 are summarized in table 2 of this
document.
Table 2--FY 2009 Fee Rates
------------------------------------------------------------------------
Animal Drug User Fee Category Fee Rate for FY 2009
------------------------------------------------------------------------
Animal Drug Application Fee.............................................
Animal drug application...................... $246,300
Supplemental animal drug application for $123,150
which safety or effectiveness data are
required or animal drug application subject
to the criteria set forth in section
512(d)(4) of the act........................
Animal drug product fee...................... $4,925
Animal drug establishment fee\1\............... $59,450
Animal drug sponsor fee\2\..................... $52,700
------------------------------------------------------------------------
\1\ An animal drug establishment is subject to only one such fee each
FY.
\2\ An animal drug sponsor is subject to only one such fee each FY.
IX. Procedures for Paying the FY 2009 Fees
A. Application Fees and Payment Instructions
The appropriate application fee established in the new fee schedule
must be paid for an animal drug application or supplemental animal drug
application subject to fees under ADUFA II that is submitted after
September 30, 2008. Payment must be made in U.S. currency by check,
bank draft, U.S. postal money order payable to the order of the Food
and Drug Administration, by wire transfer, or electronically using
Pay.gov (the ``Pay Now'' button on the cover sheet). On your check,
bank draft, or U.S. postal money order, or wire transfer, please write
your application's unique Payment Identification Number, beginning with
the letters AD, from the upper right-hand corner of your completed
Animal Drug User Fee Cover Sheet. Also write the FDA post office box
number (P.O. Box 953877) on the enclosed check, bank draft, or money
order. Your payment and a copy of the completed Animal Drug User Fee
Cover Sheet can be mailed to: Food and Drug Administration, P.O. Box
953877, St. Louis, MO, 63195-3877. If payment is made via wire
transfer, send payment to US Department of Treasury, TREAS, NYC, 33
Liberty St. New York, NY 10045, Account Name: Food and Drug
Administration, Account Number: 75060099, Routing Number: 021030004,
Swift Number: FRNYUS33. If payment is made via Pay.gov, you will first
create and submit a cover sheet for your organization, then click on
the ``Pay Now'' button. You will then be taken to the Pay.gov site to
make your payment electronically.
If you prefer to send a check by a courier such as FEDEX or UPS,
the courier may deliver the check and printed copy of the cover sheet
to: US Bank, Attn: Government Lockbox
[[Page 53258]]
953877, 1005 Convention Plaza, St. Louis, Missouri 63101. (Note: This
address is for courier delivery only. If you have any questions
concerning courier delivery contact the US Bank at 314-418-4821. This
phone number is only for questions about courier delivery.)
The tax identification number of the Food and Drug Administration
is 530196965. (Note: In no case should the check for the fee be
submitted to FDA with the application.)
It is helpful if the fee arrives at the bank at least a day or two
before the application arrives at FDA's Center for Veterinary Medicine
(CVM). FDA records the official application receipt date as the later
of the following: the date the application was received by CVM, or the
date US Bank notifies FDA that your check in the full amount of the
payment due has been received, or when the United States Treasury
notifies FDA of receipt of an electronic payment. US Bank and the
United States Treasury are required to notify FDA within 1 working day,
using the Payment Identification Number described previously.
B. Application Cover Sheet Procedures
Step One--Create a user account and password. Log onto the ADUFA
Web site at http://www.fda.gov/oc/adufa and, under the ``Forms''
heading, click on the link ``User Fee Cover Sheet.'' For security
reasons, each firm submitting an application will be assigned an
organization identification number, and each user will also be required
to set up a user account and password the first time they use this
site. Online instructions will walk you through this process.
Step Two--Create an Animal Drug User Fee Cover Sheet, transmit it
to FDA, and print a copy. After logging into your account with your
user name and password, complete the steps required to create an Animal
Drug User Fee Cover Sheet. One cover sheet is needed for each animal
drug application or supplement. Once you are satisfied that the data on
the cover sheet is accurate and you have finalized the Cover Sheet, you
will be able to transmit it electronically to FDA and you will be able
to print a copy of your cover sheet showing your unique Payment
Identification Number.
Step Three--Send the payment for your application as described in
section IX.A of this document.
Step Four--Please submit your application and a copy of the
completed Animal Drug User Fee Cover Sheet to the following address:
Food and Drug Administration, Center for Veterinary Medicine, Document
Control Unit (HFV-199), 7500 Standish Pl., Rockville, MD 20855.
C. Product, Establishment and Sponsor Fees
By December 31, 2008, FDA will issue invoices and payment
instructions for product, establishment, and sponsor fees for FY 2009
using this fee schedule. Payment will be due and payable on or before
January 31, 2009. FDA will issue invoices in November 2009 for any
products, establishments, and sponsors subject to fees for FY 2009 but
that qualified for fees after the December 2008 billing.
Dated: September 8, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-21450 Filed 9-12-08; 8:45 am]
BILLING CODE 4160-01-S